Jue Pu
Direktor/Vorstandsmitglied bei LEPU BIOPHARMA CO., LTD.
Vermögen: 59 Mio $ am 31.05.2024
Aktive Positionen von Jue Pu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Direktor/Vorstandsmitglied | 22.04.2020 | - |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 01.10.2018 | - |
Karriereverlauf von Jue Pu
Ehemalige bekannte Positionen von Jue Pu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CG ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 01.03.2019 | 01.10.2023 |
| CG ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 01.01.2010 | 01.01.2018 |
| Gründer | 01.01.2010 | 01.01.2018 |
Ausbildung von Jue Pu
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
| Stanford University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| China | 2 |
Operativ
| Director/Board Member | 4 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| LEPU BIOPHARMA CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Health Technology |